Comorbidities in multiple myeloma and implications on survival: A population-based study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSverrisdóttir, Ingigerður S
Gíslason, Gauti K
Hveding Blimark, Cecilie
Kristinsson, Sigurður Y
MetadataShow full item record
CitationSverrisdóttir IS, Rögnvaldsson S, Thorsteinsdottir S, Gíslason GK, Aspelund T, Turesson I, Björkholm M, Gregersen H, Hveding Blimark C, Landgren O, Kristinsson SY. Comorbidities in multiple myeloma and implications on survival: A population-based study. Eur J Haematol. 2021 Feb 10. doi: 10.1111/ejh.13597.
AbstractHigh proportion of patients with multiple myeloma suffer from comorbidities which may alter clinical management. Therefore, our aims were to evaluate the prevalence of comorbidities and their impact on survival. We included patients diagnosed with multiple myeloma 1990-2013 in Sweden and all diagnoses from each patient from 1985. A total of 13 656 patients with multiple myeloma were included in the study, thereof 7404 (54%) had comorbidity at diagnosis. The risk of death was increased for those with one comorbidity at diagnosis compared to those without any comorbidity (hazard ratio = 1.19; 95% confidence interval:1.14-1.25); this risk was higher for those with two (1.38; 1.30-1.47) and three or more comorbidities (1.72; 1.62-1.83). Furthermore, the risk of death was increased in patients with prior history of cancer, arrhythmia, heart failure, diabetes mellitus, cerebrovascular disease, chronic lung disease, psychological disease, peptic ulcer, neurological disease, peripheral vascular disease, chronic kidney disease, dementia, and inflammatory bowel disease. This large study shows that over 50% of multiple myeloma patients have a comorbidity at diagnosis and survival decreased with increasing numbers of comorbidities. This emphasizes the importance of comorbidities when evaluating patients and deciding on treatment strategies for individuals with multiple myeloma. Keywords: comorbidities; multiple myeloma; survival.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
Rights© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
- The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
- Authors: Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY
- Issue date: 2015 May
- The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
- Authors: Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE
- Issue date: 2015 Nov 5
- The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
- Authors: Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frølund UC, Helleberg C, Broch B, Pedersen PT, Gimsing P, Klausen TW
- Issue date: 2017 Jul
- History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
- Authors: Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, Björkholm M, Kristinsson SY
- Issue date: 2017 Feb
- Influence of specific comorbidities on survival after early-stage breast cancer.
- Authors: Ewertz M, Land LH, Dalton SO, Cronin-Fenton D, Jensen MB
- Issue date: 2018 Jan